The Manufacturers Life Insurance Company Boosts Stock Holdings in Novo Nordisk A/S $NVO

The Manufacturers Life Insurance Company lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 22.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 229,607 shares of the company’s stock after acquiring an additional 42,361 shares during the period. The Manufacturers Life Insurance Company’s holdings in Novo Nordisk A/S were worth $11,007,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership purchased a new stake in Novo Nordisk A/S during the 1st quarter valued at $287,660,000. Boston Partners purchased a new position in shares of Novo Nordisk A/S in the third quarter worth $310,199,000. Price T Rowe Associates Inc. MD raised its stake in shares of Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares during the last quarter. Voloridge Investment Management LLC lifted its holdings in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after purchasing an additional 4,302,126 shares in the last quarter. Finally, Maverick Capital Ltd. bought a new position in shares of Novo Nordisk A/S during the first quarter valued at $76,444,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NVO stock opened at $43.03 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a market cap of $192.15 billion, a P/E ratio of 10.52, a price-to-earnings-growth ratio of 1.45 and a beta of 0.74. The stock’s fifty day moving average price is $47.49 and its 200-day moving average price is $43.65.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion during the quarter. On average, equities analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is presently 20.05%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NVO shares. BMO Capital Markets reiterated a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Thursday, August 27th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $64.94.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy received approval in China for MASH, making it the first GLP-1 receptor agonist in the country approved for the liver disease. The decision expands semaglutide’s potential beyond obesity and diabetes, although Novo has not provided a launch schedule or revenue outlook. Reuters article
• Positive Sentiment: China’s acceptance of Novo’s oral Wegovy application creates a potential avenue into the country’s growing GLP-1 weight-management market. Investors see the opportunity as a possible long-term growth driver, though regulatory approval, launch timing and competitive dynamics remain uncertain. Oral Wegovy China article
• Neutral Sentiment: HSBC raised its price target to 320 Danish kroner but kept a Hold rating, reflecting improved valuation expectations without a strong near-term conviction. HSBC price target article
• Positive Sentiment: Some analysts continue to view Novo’s valuation, strong margins, free cash flow and GLP-1 leadership as providing a margin of safety, suggesting the recent weakness may already reflect substantial execution and competitive risks. Novo Nordisk valuation analysis
• Negative Sentiment: The Morgan Stanley downgrade is the dominant near-term catalyst. Investors are questioning whether oral Wegovy, China expansion and other pipeline opportunities can replace revenue exposed to the semaglutide patent cliff, contributing to NVO’s decline and keeping sentiment weak. Morgan Stanley downgrade article

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.